AI & Machine Learning– category –
-
ASCO 2026 Features AI-Augmented ctDNA Analysis for Prognostic Risk Stratification in Metastatic Clear Cell RCC, Pioneering GU Oncology Advancements
UroToday USA Overview UroToday's coverage of ASCO 2026 highlights several presentations in genitourinary oncology, prominently featuring an 'AI-Augmented Analysis of Quantitative ctDNA Burden and Longitudinal Kinetics to Identify Prognos... -
Expert Calls for AI/ML Intervention as Delayed Clinical Trial Reporting in China Sparks International Criticism
Facebook (STAT News) USA Overview Renewed criticism has emerged regarding lax clinical trial reporting practices in China, following a second delayed report of a child's death, highlighting severe regulatory compliance issues. The discus... -
TFSF Ventures Unveils AI Agent Solution for Enhanced Pharma Pipeline Competitive Intelligence
TFSF Ventures Unknown Overview TFSF Ventures highlights the application of AI agents for competitive intelligence in the pharmaceutical sector, specifically for pipeline tracking. These AI agents integrate data from critical sources such... -
Unlocking Drug Development Insights: AI-Powered CTO Benchmark Integrates LLMs and Multi-Source Data for Dynamic Clinical Trial Outcomes
Chufan Gao Unknown Overview Chufan Gao and colleagues have released the Clinical Trial Outcome (CTO) benchmark, a vast repository of 125,000 drug and biologic trials. This innovative platform integrates LLM interpretations, real-time tri... -
ASCO 2026 Reveals LITESPARK-022 Trial’s Significant DFS Improvement with Adjuvant Pembrolizumab Plus Belzutifan in Renal Cell Carcinoma
Oncodaily USA Overview New insights into adjuvant therapy for renal cell carcinoma (RCC) were presented at the 2026 ASCO Annual Meeting. The LITESPARK-022 trial demonstrated that adjuvant pembrolizumab combined with belzutifan significan... -
HER2-Targeted Regimen Achieves 60.2% Pathologic Complete Response Rate in Locally Advanced HER2-Positive Breast Cancer in China’s Phase II neoPICD Trial, Presented at ASCO Breakthrough 2026
The ASCO Post USA Overview A HER2-targeted regimen demonstrated a high pathologic complete response (pCR) rate of 60.2% in patients with locally advanced HER2-positive breast cancer in the phase II neoPICD trial conducted in China. Prese... -
ClicData Differentiates AI, ML, Deep Learning, and Data Science, Emphasizing Cost-Benefit for Varying Data Scales
ClicData USA Overview ClicData clarifies the distinct applications of AI, Machine Learning (ML), Deep Learning, and Data Science, noting that their suitability depends on problem scale. AI is presented as the overarching objective, with ... -
Coursera Demystifies AI, Machine Learning, and Deep Learning: Outlining Key Distinctions and Business Applications
Coursera USA Overview A recent Coursera article clearly delineates AI as the broad discipline mimicking human thought, with Machine Learning (ML) as a subset that uses algorithms trained on data. Deep Learning, a specialized form of ML, ... -
ASCO 2026 Highlights Critical Gap in AI Education for Oncology Fellows Amidst Widespread AI Tool Adoption for Cancer Navigation
Google Cloud (CBCN Canada) USA Overview The 2026 ASCO Annual Meeting underscored the vital role of AI in empowering cancer patients and caregivers through education and advocacy. A presented study revealed that while 74% of hematology/on... -
AI & Machine Learning Weekly Report August 2, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 02, 2026 (PDF) — Download Weekly Report August 02, 2026 (PDF) — DownloadDownload 🎙 Podcast August 02, ...
